Guardant Health EBITDA TCAC 5A

Que fait Guardant Health ? Guardant Health Inc is a French Unternehmen specializing in the development of non-invasive diagnostic tests for cancer. The company was founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz. The two founders had previously successfully founded a company specializing in the development of blood tests for pregnancy. Guardant Health's goal is to find traces of cancer cells in the blood of patients to enable early diagnosis of cancer. Based on liquid biopsy tests offered by the company, doctors can identify tumor cells and genetic mutations without having to resort to invasive methods such as tissue sampling. This allows for faster diagnosis and also enables quicker decisions regarding therapy. Guardant Health's business model is based on the commercialization of its liquid biopsy tests, which are based on specially developed DNA sequencing methods. The company offers both diagnostic tests that can help identify cancer, as well as tests that can assist doctors in monitoring the success of cancer therapies. Guardant Health has focused its offering on several products and divisions, including Guardant360, GuardantOmni, and GuardantReveal. Each of these products aims to solve specific challenges related to the diagnosis and treatment of cancer. Guardant360 is a diagnostic test specifically designed to help doctors sequence the DNA of cancer cells in patients' blood and identify the genetic alterations that contribute to tumor growth. On the other hand, GuardantOmni is a liquid biopsy test that targets a broader range of cancer types. It allows for a comprehensive genetic scan of cancer cells in the blood to identify specific mutations that can help in tracking disease progression and choosing appropriate therapy. GuardantReveal is a test focused on monitoring patients at increased risk for cancer. The test can be used to detect early signs of tumors in patients who are at higher risk due to their family history, age, or other factors. Guardant Health has achieved considerable success in the field of liquid biopsy detection in recent years. Currently, over 100,000 patients worldwide have access to Guardant Health's liquid biopsy-based tests. The company is headquartered in Redwood City, California and employs over 1,000 people. It has a broad investor base including The SoftBank Vision Fund, Sequoia Capital, Lightspeed Venture Partners, and Khosla Ventures. Overall, the company has raised over $550 million in financing. Guardant Health aims to revolutionize the world of cancer diagnostics and treatment. By radically changing the process of diagnosing and monitoring cancer patients, the company seeks to improve the survival rate of cancer patients and make cancer treatment more effective overall. Guardant Health est l'une des entreprises les plus populaires sur Eulerpool.